Carus Animal Health and Intract Pharma Limited (“Intract”) have entered into an agreement to develop Intract’s novel drug delivery technologies for application in the veterinary market for treatment of companion animals.


Intract, a UK company specialising in development of oral drug formulations, has developed unique models and proprietary drug delivery technologies to develop advanced new products with optimal therapeutic effectiveness. It is now working in a program with Carus to develop a novel formulation with optimised drug release characteristics. Details of the drug products under development have not been disclosed.


In addition to Intract’s advanced drug delivery systems, Intract offers in depth understanding and know-how relating to all aspects of oral drug delivery, and offers in vitro and ex vivo models which utilise biological fluids and tissue samples from relevant animal species to provide unparalleled insights into drug stability, solubility and permeability throughout the highly variable intestinal environment.


Using the data from these studies, Intract can develop optimal, state-of-the-art drug delivery systems to target and control drug release in the ideal region of the gut. In the collaboration with Carus, these novel formulations are now being used bring innovation and commercially superior drug products to the veterinary market.


Jolian Howell, commercial director at Carus Animal Health, said: “We are excited about the prospect of developing technologies created to benefit human health to offer unique benefits to animal health in terms of oral administration through a range of controlled release technologies.”


Bill Lindsay, CEO of Intract Pharma said “Intract is delighted to be working with Carus, an established international player in the field of veterinary medicine, to develop novel products to benefit animal health”.




Notes to Editors:


Carus Animal Health is based in the UK and was established in 2017. Its parent company, Kyoritsu Seiyaku, is the biggest animal health company in Japan and ranked number 11 in global markets.

Intract Pharma is a licensing and product development company offering state of the art formulation technologies and specialist gastrointestinal models to develop advanced new therapeutics. These have been successfully developed for multiple therapies in human health.

Intract is a spin-out from the UCL School of Pharmacy based on more than 20 years of research from the laboratory of Prof. Abdul Basit.


For further information contact:

Jolian Howell
Commercial Director
Carus Animal Health
+44 (0)7921 516 286

Mike Keeler
Garnett Keeler PR
+44 (0)20 8647 4467


London, England, 27th March 2019.

Intract Pharma has announced the launch of a first product incorporating its colon targeting technology, Phloral®. The product, called Yaldigo®/Asacol 1600 which has been created and is marketed by Tillotts Pharma AG, Switzerland, is a novel therapeutic for treatment of ulcerative colitis which incorporates Phloral® to facilitate targeting of the drug product to the site of disease in the colon.

Phloral® utilises a unique dual-trigger mechanism to ensure accurate release of the drug in the colon, irrespective of gastrointestinal transit time and pH. The unique Phloral ® mechanism, in which drug release is achieved through the actions of enzymes specifically produced by the colonic microbiome is available exclusively through Intract Pharma.

The Phloral® technology has been licensed to Tillotts Pharma AG for use with mesalazine and is available for licence from Intract for other drugs.

Commenting, Bill Lindsay, CEO of Intract said “Launch of the Tillotts Product is a landmark for Intract Pharma and provides further validation of our Phloral technology as the only clinically proven means to reliably and consistently target the colon”

Intract offers the Phloral® technology under licence and is developing Phloral®-based products in-house for out-licensing into clinical development.

For more information please contact us at or call +44 (0)20 7691 4918.

Finch Therapeutics and OpenBiome have developed an orally administered microbial therapy for recurrent C. difficile infection.

FIN-403 harnesses the power of Phloral® to target delivery of healthy microbiota to the site of infection in the colon. FIN-403 demonstrated 88% per-protocol efficacy in an initial dose-finding study with 26 patients. DNA sequencing also showed successful and stable engraftment of the full diversity of the healthy microflora.